ArticleBMC pharmacology & toxicology2025
Mangiferin: a novel hepatoprotective for liver cirrhosis via modulation of histological, cellular, biochemical, inflammatory markers and oxidative stress.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Astragalin Suppresses Colorectal Carcinogenesis by Targeting Proliferation, Oxidative Stress, and Inflammation.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimLiver cirrhosis is a global syndrome that develops from activation and proliferation of hepatic stellate cells, and following extracellular matrix accumulation. The current study evaluates the acute toxicity and prophylactic effects of mangiferin in thioacetamide (TAA)-induced liver damage in rats and its causal mechanisms. EXPERIMENTAL PROCEDURE: Thirty Sprague–Dawley rats were separate into five groups and treated for two months as follows: group (A) normal ingested orally daily 10% Tween 20 + distilled water (i.p.) (three times weekly); group (B) TAA control rats treated by mouth daily 10% Tween 20 + 200 mg/kg TAA i.p. (three times weekly); group (C) reference group received daily oral dose of 50 mg/kg silymarin + 200 mg/kg TAA i.p. (three times weekly); groups (D) rats received oral daily 30 mg/kg mangiferin + 200 mg/kg TAA i.p. (three times weekly); group (E) received oral daily 60 mg/kg mangiferin + 200 mg/kg TAA i.p. (three times weekly) for two months.
resultsThe non-toxic effects of mangiferin were evidenced by the lack of any toxicity incidence in rats ingested with up to 500 mg/kg. Gross morphological examination showed a regular liver architecture in mangiferin fed collections compared to hepatotoxic cluster. Histology of rat’s liver fed with mangiferin showed an important decrease in the liver index with hepatic cells propagation, mild cellular injury. Macroscopy of hepatotoxic liver exhibited irregular, rough surface with micro and macro nodules, and histopathology-stained Hematoxylin and Eosin (H&E), and Masson’s Trichome exhibited inflammation infiltration of lymphocytes, focal necrosis, fibrosis, and bile duct propagation. Immunohistochemistry examination of proliferation cellular nucleus antigen (PCNA), TAA inoculation stimulated cellular proliferation and apoptotic actions in damaged liver tissues, designated by increased PCNA. The TAA intraperitoneal inoculation caused significant hepatic dysfunction (lowered total protein, albumin levels, hepatotoxicity, and necrotic cell propagation). The TAA injection aggravated important hepatic intoxication inveterate by histopathological symptoms; change of tissue architecture, cellular propagation, and endothelial harm, enlarged hepatic nucleus, cytoplasmic vacuolation, collagen deposition, and raised necrotic tissues. The oxidative stress and inflammation process was markedly commenced subsequent TAA conveyance to rats proved by down-regulation of SOD, CAT, and IL-10, while, up-regulating the MDA and TNF-α and IL-6 cytokines.
conclusionNo toxicological signs were observed in rats administered 500 mg/kg of Mangiferin. Mangiferin supplementation showed significant resistance against TAA-mediated hepatotoxicity, reversed those cellular alterations, and restored liver functions. These results demonstrate significant ameliorative effects of mangiferin in TAA hepatotoxic rats, which could be attributed to its anti-apoptotic, antioxidant, and anti-inflammatory potentials, making it a possible viable hepatoprotective agent for inflammatory-related hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.